SenzaGen’s Year-end report 2021: Strong performance with more than 150% growth in H2 and nearly doubled sales for full year
SenzaGen broadens non-animal offering for medical devices with more tests and tailored consulting services – strengthens market presence and realizes synergies from acquisition
SenzaGen receives SEK 1m follow-on order for GARD®skin Dose-Response from one of the world’s largest cosmetics companies
